Advertisement

Gastrolesività e steroidi: miti e realtà

  • Giulia Giancola
  • Giorgio ArnaldiEmail author
RASSEGNA

Sommario

La profilassi con inibitore di pompa protonica (PPI) nei pazienti in concomitante trattamento steroideo o negli stati di ipercortisolismo è argomento ad oggi molto dibattuto in quanto, a differenza dell’accertato rischio trombotico correlato all’eccesso di glucocorticoidi, non ci sono dati certi sul rischio emorragico; pertanto, qualora quest’ultimo fosse assente, la profilassi con PPI, oltre a non apportare benefici gastroenterici, aumenterebbe anche il rischio di effetti collaterali correlati a questi farmaci.

Parole chiave

Terapia steroidea Ipercortisolismo Gastrolesività PPI 

Notes

Conflitto di interessi

Gli autori Giulia Giancola e Giorgio Arnaldi dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi su animali

Gli autori di questo articolo non hanno eseguito studi sugli animali.

Supplementary material

40619_2019_584_MOESM1_ESM.doc (27 kb)
(DOC 27 kB)
40619_2019_584_MOESM2_ESM.doc (26 kb)
(DOC 26 kB)

Bibliografia

  1. 1.
    Trementino L, Arnaldi G, Appolloni G et al. (2010) Coagulopathy in Cushing’s syndrome. Neuroendocrinology 928(Suppl 1):55–59 CrossRefGoogle Scholar
  2. 2.
    Van Der Pas R, Leebeek FW, Hofland KJ et al. (2013) Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol 78:481–488 CrossRefGoogle Scholar
  3. 3.
    Hatipoglu E, Caglar AS, Caglar E et al. (2015) Peptic ulcer disease in endogenous hypercortisolism: myth or reality? Endocrine 50(2):489–495 CrossRefGoogle Scholar
  4. 4.
    Garcia Rodríguez LA, Hernández-Díaz S (2001) The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 3(2):98–101 CrossRefGoogle Scholar
  5. 5.
    Weil J, Langman MJ, Wainwright P et al. (2000) Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 46(1):27–31 CrossRefGoogle Scholar
  6. 6.
    Dorlo TP, Jager NG, Beijnen JH, Schellens JH (2013) Concomitant use of proton pump inhibitors and systemic corticosteroids. Ned Tijdschr Geneeskd 157(19):A5540 Google Scholar
  7. 7.
    Conn HO, Blitzer BL (1976) Non association of adrenocorticosteroid therapy and peptic ulcer. N Engl J Med 294(9):473–479 CrossRefGoogle Scholar
  8. 8.
    Conn HO, Poynard TJ (1994) Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. Int Med 236(6):619–632 CrossRefGoogle Scholar
  9. 9.
    Conn HO, Poynard T (1984) Adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 310(3):201–202 CrossRefGoogle Scholar
  10. 10.
    Narum S, Westergren T, Klemp M (2014) Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. BMJ Open 4(5):e004587 CrossRefGoogle Scholar
  11. 11.
    Messer J, Reitman D, Sacks HS et al. (1983) Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 309(1):21–24 CrossRefGoogle Scholar
  12. 12.
    Guslandi M (2013) Steroid ulcers: any news? World J Gastrointest Pharmacol Ther 4(3):39–40 CrossRefGoogle Scholar
  13. 13.
    Butler E, Møller MH, Cook O et al. (2018) Corticosteroids and risk of gastrointestinal bleeding in critically ill adults: Protocol for a systematic review. Acta Anaesthesiol Scand 62(9):1321–1326 CrossRefGoogle Scholar
  14. 14.
    Martínek J, Hlavova K, Zavada F et al. (2010) “A surviving myth”—corticosteroids are still considered ulcerogenic by a majority of physicians. Scand J Gastroenterol 45(10):1156–1161 CrossRefGoogle Scholar
  15. 15.
    Munson JC, Wahl PM, Daniel G et al. (2012) Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Saf 21(4):366–374 CrossRefGoogle Scholar
  16. 16.
    Chrousos GA, Kattah JC, Beck RW, Cleary PA (1993) Side effects of glucocorticoid treatment. Experience of the optic neuritis treatment trial. JAMA 269(16):2110–2112 CrossRefGoogle Scholar
  17. 17.
    Caplan A, Fett N, Rosenbach M et al. (2017) Prevention and management of glucocorticoid-induced side effects: A comprehensive review: Gastrointestinal and endocrinologic side effects. J Am Acad Dermatol 76(1):11–16 CrossRefGoogle Scholar
  18. 18.
    Brouwer MC, McIntyre P, Prasad K, van de Beek D (2015) Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev 9:CD004405 Google Scholar
  19. 19.
    Alderson P, Roberts I (2005) Corticosteroids for acute traumatic brain injury. Cochrane Database Syst Rev 1:CD000196 Google Scholar
  20. 20.
    Annane D, Bellissant E, Bollaert PE et al. (2015) Corticosteroids for treating sepsis. Cochrane Database Syst Rev 12:CD002243 Google Scholar
  21. 21.
    Zilio M, Mazzai L, Sartori MT et al. (2016) A venous thromboembolism risk assessment model for patients with Cushing’s syndrome. Endocrine 52(2):322–332 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Clinica di Endocrinologia e Malattie del Metabolismo, Università Politecnica delle MarcheOspedali Riuniti di AnconaAnconaItalia

Personalised recommendations